Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company focused on discovering, developing and delivering potentially curative therapies that address the underlying drivers of heart disease. The Tenaya Therapeutics news feed highlights company announcements, clinical data updates and financial disclosures related to its gene therapy and small molecule programs for genetic cardiomyopathies and heart failure.
News about Tenaya frequently centers on TN-201, its AAV9-based gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, its AAV9-based gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Company press releases provide interim safety, biopsy and early efficacy results from the MyPEAK-1 and RIDGE-1 Phase 1b/2 clinical trials, including observations on protein expression, arrhythmia measures and biomarkers.
Investors and followers of TNYA can also find updates on regulatory interactions, such as FDA designations and clinical hold communications, as well as information on Tenaya’s capital-raising activities through public offerings described in SEC filings and related press releases. Additional news items cover participation in scientific and investor conferences, late-breaking presentations at major cardiology and gene therapy meetings, and publications that describe Tenaya’s research platforms and preclinical findings.
This page aggregates these disclosures so readers can review Tenaya Therapeutics’ latest reported milestones, from clinical trial progress for TN-201 and TN-401 to developments in its broader pipeline, including the TN-301 small molecule HDAC6 inhibitor and early-stage preclinical programs. For those tracking TNYA, the news stream offers a consolidated view of how the company reports advancing its mission to address genetic drivers of heart disease.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) reported significant progress in 2021, marking milestones in research and manufacturing as it transitions into a clinical-stage company. The fourth-quarter report indicated a net loss of $72.7 million, or $4.10 per share, compared to $38.4 million, or $39.50 per share, in 2020. The company strengthened its leadership team with notable appointments and expects to submit several IND applications to the FDA in 2022 and 2023. As of December 31, 2021, Tenaya's cash reserves stood at $251.3 million, supporting operations into the second half of 2023.
Tenaya Therapeutics, a biotechnology firm focused on heart disease therapies, has announced its participation in several investor conferences. Key events include the Cowen 2nd Annual Genetic Medicines Summit on February 3, 2022, and the SVB Leerink Global Healthcare Conference on February 18, 2022. The company aims to develop curative treatments addressing genetic and prevalent heart conditions through gene therapy, cellular regeneration, and precision medicine. Founded by leading scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is committed to advancing heart disease treatment.
Tenaya Therapeutics (NASDAQ:TNYA) has selected TN-401 as a candidate gene therapy for treating genetic Arrhythmogenic Right Ventricular Cardiomyopathy (gARVC) caused by PKP2 gene mutations, which affect over 70,000 patients in the U.S. Additionally, the company plans to submit IND applications for TN-201 and TN-301 in the latter half of 2022. Tenaya has appointed Jennifer Drimmer as General Counsel, bringing over 17 years of experience. The company aims to advance several therapeutic candidates towards clinical trials while enhancing its operational capabilities.
Tenaya Therapeutics (NASDAQ: TNYA) announced two key appointments: Karah Parschauer to its Board of Directors and Joanna Auch as Senior VP of People and Culture. These appointments aim to strengthen Tenaya's leadership amid its transition to a public company with over 100 employees. CEO Faraz Ali highlighted that both individuals bring valuable experience and will enhance the company's capabilities in drug development for heart disease. Parschauer has extensive biopharmaceutical experience and previously held roles at Ultragenyx, while Auch has over 15 years in HR.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced significant changes to its Board of Directors, with the appointment of Dr. June Lee, who brings extensive experience in cardiovascular drug development. Dr. Lee was previously the Founder and CEO of Esker Therapeutics and held senior roles at MyoKardia and Genentech. She succeeds Dr. JJ Kang, who steps down after five years to focus on other ventures. The move reflects Tenaya's evolution towards becoming a clinical-stage company as it aims to advance therapies for heart disease.
Tenaya Therapeutics (NASDAQ: TNYA), a biotechnology firm focused on heart disease therapies, announces CEO Faraz Ali's participation in the 33rd Annual Piper Sandler Healthcare Conference from November 29 to December 2. A fireside chat webcast will be available starting November 22, 2021, at 10:00 a.m. ET. Founded by top cardiovascular scientists, Tenaya is dedicated to developing innovative treatments for both rare and common heart conditions through Gene Therapy, Cellular Regeneration, and Precision Medicine.
Tenaya Therapeutics, a biotechnology firm, reported significant advancements in its gene therapy programs and third quarter 2021 financial results. The company initiated a global natural history study for children with MYBPC3 mutations to enhance the TN-201 gene therapy development. Preclinical data demonstrated promising outcomes in murine models, highlighting durability in disease reversal. Tenaya's cash position stands strong at $280.5 million post-IPO, expected to sustain operations through late 2023. Despite a net loss of $18.3 million, the company continues its progress towards clinical-stage development.
Summary not available.
Tenaya Therapeutics (NASDAQ: TNYA) announced that CEO Faraz Ali will participate in multiple key biotechnology conferences in October. Events include the Chardan 5th Annual Genetic Medicines Conference on October 4, featuring a panel discussion and a fireside chat. Ali will also speak at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on October 13, followed by a company presentation. Lastly, he will present at the Jefferies Gene Therapy/Editing Summit on October 28. Tenaya focuses on innovative therapies for heart disease.
Tenaya Therapeutics (TNYA) announced significant developments, including the granting of Orphan Drug Designation for its TN-201 gene therapy for genetic HCM by the FDA. The company successfully completed its IPO on August 3, 2021, raising $207 million. Leadership changes include Leone Patterson as Chief Financial Officer and Matt Pollman as SVP of Clinical Development. Financial results for Q2 2021 show a net loss of $15.2 million and R&D expenses of $10.9 million. Tenaya anticipates submitting IND applications for TN-201 and TYA-11631 in 2022.